Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07802717 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma

Name: A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma — clinical trial record (NCT07802717)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorVyriad, Inc.

Started2026-09-08

View on ClinicalTrials.gov ↗

A Phase 1, first in human, study to evaluate the safety and the effects of in vivo BCMA-CAR T cell therapy (VV169) in patients with Multiple Myeloma that has been previously treated and has come back, or does not respond to standard treatments. Eligible patients will receive VV169, a T-cell targeted lentiviral vector, via infusion. Patients will be monitored for safety and tolerability for up to 2 years, until progressive disease or start of next treatment, whichever is earlier.

Trial Details

NCT Number	NCT07802717
Lead Sponsor	Vyriad, Inc. Collaborators: Mayo Clinic
Conditions	Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Enrollment	40 participants
Start Date	2026-09-08
Primary Completion	2027-08-31 (estimated)
Study Completion	2029-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-03